Record Revenue Growth
2024 was a record year for ALK with revenue up 15%, driven primarily by European tablet sales. Earnings improved by 65% in local currencies, and the EBIT result exceeded DKK1 billion for the first time.
European Market Performance
Europe stood out as an exceptional contributor to growth, with sales up 22% and European tablet sales increasing by 31%. ALK consolidated its position as the European market leader.
Successful Execution of Allergy+ Strategy
The Allergy+ strategy started delivering desired results, expanding addressable market in respiratory allergy, and building new revenue streams in the broader allergy space.
Neffy Nasal Spray Launch
ALK entered the largest in-licensing deal in its history with the rights for Neffy, a nasal spray for emergency treatment. Launch preparations are underway, with expectations to contribute to growth from the second half of the year.
Sustainability and Optimization Initiatives
ALK implemented optimization initiatives generating savings of more than DKK300 million in '25, exceeding the original target of DKK250 million.